<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02579161</url>
  </required_header>
  <id_info>
    <org_study_id>14-003</org_study_id>
    <nct_id>NCT02579161</nct_id>
  </id_info>
  <brief_title>Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy</brief_title>
  <official_title>Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Investigators objective is to compare the clinical efficacy of a single-day protocol with
      a short-course protocol for PCNL. The investigator hope is to reduce the use of possibly
      unnecessary prolonged antibiotic use, reduce hospital costs and prevent the further
      propagation of resistant microbes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For large renal stone burdens and/or complex stones, Percutaneous Nephrolithotomy (PCNL) has
      become the mainstay for treatment, replacing open kidney stone surgery since it's
      introduction in 1976. However, PCNL is not without its complications, specifically
      infectious. The procedure carries up to 25% incidence of infectious complications with
      approximately 1% rate of severe sepsis even with completely sterile conditions. Therefore,
      the use of antibiotics becomes paramount, but to date there are no PNCL specific guidelines
      for the appropriate duration and class of antibiotics. This fact leaves the practicing
      urologists to their own subjective experiences to the guide them. In addition, in an age
      where there are increasing numbers of resistant microbes the judicious use of antibiotics is
      in even more paramount.

      The investigators of this project, purpose a randomized intention to treat prospective study
      to explore the duration and type of antibiotics in a larger population then previously
      studied. The investigators hypothesize that there will be no difference in complications
      between two groups: 1) 24 hours of perioperative antibiotics versus 2) Continued antibiotics
      until the removal of any external catheters. The investigators will model the antibiotics
      choices and duration after the 2013 American Urological Association, (AUA) Urologic Surgery
      Antimicrobial Prophylaxis recommendations, modified by our local antibiogram as necessary.
      The investigators' objective is to compare the clinical efficacy of a single-day protocol
      with a short-course protocol for PCNL. Our hope is to reduce the use of possibly unnecessary
      prolonged antibiotic use, reduce hospital costs and prevent the further propagation of
      resistant microbes.

      Antibiotic detail: cephalosporins or aminoglycoside + metronidazole or clindamycin and the
      alternative for allergies being aminoglycoside/ sulbactam or fluoroquinolone

      Looking at the same drugs and doses the variable is the timeframe of the medication
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of antibiotic dosing</measure>
    <time_frame>2 years</time_frame>
    <description>Compare the clinical efficacy of a single-dose protocol (antibiotics for 24 hours) with a short-course protocol (antibiotics continued until external catheters are removed) for PCNL. Looking at complication rate differences</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Kidney Stones</condition>
  <arm_group>
    <arm_group_label>Antibiotics for a 24 hour period</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antibiotics for a 24 hour period
Intervention drug to be determined based on patient history etc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continued antibiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continued antibiotics until the removal of any external catheters
Intervention drug to be determined based on patient history etc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cephalosporins</intervention_name>
    <description>Looking at the same drugs and doses the variable is the timeframe of the medication</description>
    <arm_group_label>Antibiotics for a 24 hour period</arm_group_label>
    <arm_group_label>Continued antibiotics</arm_group_label>
    <other_name>or + metronidazole or clindamycin and the alternative for allergies being aminoglycoside/ sulbactam or fluoroquinolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aminoglycoside</intervention_name>
    <arm_group_label>Antibiotics for a 24 hour period</arm_group_label>
    <arm_group_label>Continued antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metronidazole</intervention_name>
    <arm_group_label>Antibiotics for a 24 hour period</arm_group_label>
    <arm_group_label>Continued antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin</intervention_name>
    <arm_group_label>Antibiotics for a 24 hour period</arm_group_label>
    <arm_group_label>Continued antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aminoglycoside/ sulbactam</intervention_name>
    <description>If allergies to above medicines</description>
    <arm_group_label>Antibiotics for a 24 hour period</arm_group_label>
    <arm_group_label>Continued antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoroquinolones</intervention_name>
    <arm_group_label>Antibiotics for a 24 hour period</arm_group_label>
    <arm_group_label>Continued antibiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;18 years old

          -  Negative urine culture within 1 month prior to procedure

          -  Renal Calculi which would optimally require PCNL for treatment.

        Exclusion Criteria:

          -  Patients &lt;18 years old.

          -  Patients who are not able to give consent for study

          -  Patients currently on antibiotics immediately prior to the procedure

          -  Previous history of sepsis or SIRS from stone manipulations

          -  Foley catheter in place for greater than 1 week duration

          -  Patients under going planned, multi-staged procedures

          -  Immunosuppressed patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zeph Okeke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeph Okeke, MD</last_name>
      <phone>516-734-8500</phone>
      <email>Zokek@nshs.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dave Leavitt, MD</last_name>
      <phone>516-734-8500</phone>
      <email>Dleavitt@nshs.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Zeph Okeke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dave Leavitt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bradley Morganstern, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeph Okeke, MD</last_name>
      <phone>516-734-8500</phone>
      <email>zokeke@nshs.edu</email>
    </contact>
    <investigator>
      <last_name>Zeph Okeke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Leavitt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bradley Morganstern, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2014</study_first_submitted>
  <study_first_submitted_qc>October 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2015</study_first_posted>
  <last_update_submitted>September 28, 2017</last_update_submitted>
  <last_update_submitted_qc>September 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Zeph Okeke</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Percutaneous Nephrolithotomy</keyword>
  <keyword>Kidney Stones</keyword>
  <keyword>Antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Sulbactam</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

